The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections

Current Opinion in Immunology

Volumn 11, Issue 4, 1999, Pages 420-426

  Finkelman, Fred D ^a,b   Wynn, Thomas A ^c   Donaldson, Debra D ^d   Urban Jr , Joseph F ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d PFIZER INC   (United States)

^e AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4;

CYTOKINE PRODUCTION; HELMINTHIASIS; HOST RESISTANCE; HUMAN; INFECTION CONTROL; INFLAMMATION; NEMATODIASIS; REVIEW;

EID: 0033178829     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)80070-3     Document Type: Article

References (85)

1. Finkelman FD, Shea-Donohue T, Goldhill J, Sullivan CA, Morris SC, Madden KB, Gause WC, Urban JF Jr: Cytokine regulation of host defense against parasitic gastrointestinal helminths: Lessons from studies with rodent models. Annu Rev Immunol 1997, 15:505-533.
2. Svetic A, Madden KB, di Zhou X, Lu P, Katona IM, Finkelman FD, Urban JF Jr, Gause WC: A primary intestinal helminthic infection rapidly induces a gut-associated elevation of Th2-associated cytokines and IL-3. J Immunol 1993, 150:3434-3441.
3. Finkelman FD, Katona IM, Urban JF Jr, Holmes J, Ohara J, Tung AS, Sample JVG, Paul WE: Interleukin-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988, 141:2335-2341.
4. Madden KB, Urban JF Jr, Ziltener HJ, Schrader JW, Finkelman FD, Katona I: Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol 1991, 147:1387-1391.
5. Rankin JA, Picarella DE, Geba G, Temann U-A, Prasad B, DiCosmo B, Tarallo A, Stripp B, Whitsett J, Flavell RA: Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: Lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA 1996, 93:7821-7825.
6. Goldhill J, Morris SC, Maliszewski C, Urban JF Jr, Funk CD, Finkelman FD, Shea-Donohue T: Interleukin-4 modulates cholinergic neural control of mouse small intestinal longitudinal muscle. Am J Physiol 1997, 272:G1135-G1140.
7. Coffman RL, Seymour BWP, Hudak S, Jackson J, Rennick D: Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989, 245:308-310.
8. McKenzie GJ, Bancroft A, Grencis RK, McKenzie ANJ: A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr Biol 1998, 8:339-342. IL-13-knockout mice, unlike IL-4-knockout mice, fail to expel N. brasiliensis efficiently and fail to generate goblet cell hyperplasia even though they develop a strong Th2 response to infection. IL-13 treatment reduces worm numbers in IL-13-deficient mice.
9. LeGros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE: Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 1990, 172:921-929.
10. O'Garra A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
11. + T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci USA 1997, 94:10838-10843.
12. Gately MK, Renzetti LM, Magram H, Stern AS, Adorini L, Gubler U, Presky DH: Interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 1998, 16:495-521.
13. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G, de Vries JE: Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-γ or IL-10. J Immunol 1993, 151:6370-6381.
14. 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 1997, 185:817-824.
15. Gollob JA, Kawasaki H, Ritz J: Interferon-γ and interleukin-4 regulate interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol 1997, 27:647-652.
16. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JR, Locksley RM: Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996, 183:109-117.
17. Urban JF Jr, Katona IM, Paul WE, Finkelman FD: Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice. Proc Natl Acad Sci USA 1991, 88:5513-5517.
18. Else KJ, Finkelman FD, Maliszewski CR, Grencis RK: Cytokine mediated regulation of chronic intestinal helminth infection. J Exp Med 1994, 179:347-351.
19. Urban JF Jr, Maliszewski CR, Madden KB, Katona IM, Finkelman FD: Interleukin-4 treatment can cure established gastrointestinal nematode infections in immunocompetent and immunodeficient mice. J Immunol 1995, 154:4675-4684.
20. Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD: IL-13, IL-4Rα, and stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 1998, 8:255-264. IL-4Rα-deficient and Stat6-deficient mice fail to expel N. brasiliensis whereas IL-4-deficient mice expel this parasite. Both IL-4 and IL-13 contribute to N. brasiliensis expulsion but IL-13 appears to be more important for expulsion than IL-4. Stat6 is not required for IgG1 responses to this parasite and inhibits IL-4 mediated induction of mucosal mastocytosis.
21. Barner M, Markus M, Brombacher F, Kopf M: Differences between IL-4Rα-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr Biol 1998, 8:669-672. IL-4Rα, unlike IL-4, is required for control of N. brasiliensis infection and Th2 development during infection - as characterized by cytokine production. Expression of the transcription factor GATA-3 and the cell surface receptor CD30 are more severely affected in IL-4Rα-deficient mice than in IL-4-deficient mice. Injection of recombinant IL-13 induces worm expulsion in mice in which a defect in the Rag2 gene causes B and T lymphocyte deficiency.
22. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993, 12:2663-2670.
23. Zurawski SM, Chomarat P, Djossou O, Bidaud C, McKenzie AN, Miossec P, Banchereau J, Zurawski G: The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995, 270:13869-13878.
24. Smerz-Bertling C, Duschl A: Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140 kDa subunit of the interleukin 4 receptor. J Biol Chem 1995, 270:966-970.
25. Obiri NI, Debinski W, Leonard WJ, Puri RK: Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995, 270:8797-8804.
26. Brown KD, Zurawski SM, Mosmann TR, Zurawski G: A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 1989, 142:679-687.
27. McKenzie ANJ, Li X, Largaespada DA, Sato A, Kaneda A, Zurawski SM, Doyle EL, Milatovic A, Francke U, Copeland NG et al.: Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993, 150:5436-5444.
28. McKenzie ANJ, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S et al.: Interleukin-13, a T-cell-derived cytokine that regulates human monocyte and B cell function. Proc Natl Acad Sci USA 1993, 90:3735-3739.
29. Minty A, Chalon P, Derocq J-M, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B et al.: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993, 362:248-250.
30. Morgan JG, Dolganov GM, Robbins SE, Hinton LM, Lovett M: The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes. Nucleic Acids Res 1992, 20:5173-5179.
31. Zurawski G, de Vries JE: Interleukin 13, an interleukin-4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994, 15:19-26.
32. de Vries JE: The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998, 102:165-169.
33. Li L, Xia Y, Nguyen A, Lai YH, Feng L, Mosmann TR, Lo D: Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999, 162:2477-2487.
34. Endo T, Ogushi F, Sone S: LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not by IFN-γ. J Immunol 1996, 156:2240-2246.
35. Doherty TM, Kastelein R, Menon S, Andrade S, Coffman RL: Modulation of murine macrophage function by IL-13. J Immunol 1993, 151:7151-7160.
36. Sozzani P, Cambon C, Vita N, Seguelas MH, Caput D, Ferrara P, Pipy B: Interleukin-13 inhibits protein kinase C-triggered respiratory burst in human monocytes. Role of calcium and cyclic AMP. J Biol Chem 1995, 10:5084-5088.
37. Yanagawa H, Sone S, Haku T, Mizuno K, Yano S, Ohmoto Y, Ogura T: Contrasting effect of interleukin-13 on interleukin-1 receptor antagonist and proinflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 1995, 12:71-76.
38. Colotta F, Saccani S, Giri JG, Dower SK, Sims JE, Introna M, Montovani A: Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol 1996, 156:2534-2541.
39. Dubois GR, Schweizer RC, Versluis C, Bruijnzeel-Koomen CA, Bruijnzell PL: Human eosinophils consititutively express a functional interleukin-4 receptor: Interleukin-4-induced priming of chemotactic responses and induction of PI-3 kinase activity. Am J Respir Cell Mol Biol 1998, 19:691-699.
40. Yu CR, Kirken RA, Malabarba MG, Yound HA, Ortaldo JR: Differential regulation of the Janus kinase-STAT pathway and biologic function of IL-13 in primary human NK and T cells: A comparative study with IL-4. J Immunol 1998, 161:218-227.
41. c chain does not function as a subunit shared by the IL-4 and IL-13 receptors. Implication for the structure of the IL-4 receptor. J Immunol 1995, 155:9-12.
42. Shen BJ, Hage T, Sebald W: Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor a chain interaction. A biosensor study employing recombinant interleukin-4-binding protein. Eur J Biochem 1996, 240:252-261.
43. Fernandez-Botran R, Vitetta ES: A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc Natl Acad Sci USA 1990, 87:4202-4206.
44. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA: Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 1996, 93:497-501.
45. Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE et al.: Interleukin-2-receptor γ chain: A functional component of the interleukin-4 receptor. Science 1993, 262:1880-1883.
46. Wang LM, Michieli P, Lie WR, Liu F, Lee CC, Minty A, Sun XJ, Levine A, White MF, Pierce JH: The insulin receptor substrate-1-related 4PS substrate but not the interleukin-2R γ chain is involved in interleukin-13-mediated signal transduction. Blood 1995, 86:42128-4227.
47. 1. J Immunol 1998, 161:2317-2324.
48. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S: Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996, 157:3220-3222.
49. c chain. J Clin Invest 1996, 98:604-609.
50. Schnyder B, Lahm H, Woerly G, Odartchenko N, Ryftel B, Car BD: Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1. Biochem J 1996, 315:767-774.
51. Murata T, Noguchi PD, Purl RK: IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: Similarities between IL-4 and IL-13 signaling. J Immunol 1996, 156:2972-2978.
52. Keegan AD, Johnston JA, Tortolani PJ, McReynolds LF, Kinzer C, O'Shea JJ, Paul WE: Similarities and differences in signal transduction by interleukin 4 and interleukin 13: Analysis of Janus kinase activation. Proc Natl Acad Sci USA 1995, 92:7681-7685.
53. Welham MJ, Learmonth L, Bone H, Schrader JW: Interleukin-13 signal transduction in lymphohemopoietic cells. Similarities and differences in signal transduction with interleukin-4 and insulin. J Biol Chem 1995, 270:12286-12296.
54. Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, Simpson RJ, Alexander WS, Metcalf D, Nicola NA: Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned IL-13 receptor and IL-4 receptor α-chains. J Biol Chem 1997, 272:9474-9480.
55. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ: cDNA cloning and characterization of the human interleukin-13 receptor α chain. J Biol Chem 1996, 271:2965-2970.
56. 1, chain and reconstitution with the IL-4Rα of a functional IL-4/IL-13 receptor complex. FEBS Lett 1997, 401:163-166.
57. Gauchat J-F, Schlagenhauf E, Feng N-P, Moser R, Yamage M, Jeannin P, Alouani S, Elson G, Notarangelo LD, Wells T et al.: A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol 1997, 27:971-978.
58. c chain. Blood 1996, 87:4286-4295.
59. Kotowicz K, Callard RE, Friedrich K, Matthews DJ, Klein N: Biological activity of IL-4 and IL-13 on human endothelial cells: Functional evidence that both cytokines act through the same receptor. Int Immunol 1996, 8:1915-1925.
60. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B: IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998, 10:1421-1433.
61. c in the IL-4 receptor. J Immunol 1995, 154:1596-1605.
62. Orchansky PL, Ayres SD, Hilton DJ, Schrader JW: An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. J Biol Chem 1997, 272:22940-22947.
63. Ruetten H, Thiemermann C: Interleukin-13 is a more potent inhibitor of the expression of inducible nitric oxide synthase in smooth muscle cells than in macrophages: A comparison with interleukin-4 and interleukin-10. Shock 1997, 8:409-414.
64. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P: Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem 1996, 271:16921-16926.
65. 2. Lab Invest 1998, 78:591-602.
66. + T cells, analyzed at the single cell level. J Exp Med 1996, 184:473-483.
67. Luttmann W, Matthiesen T, Matthys H, Virchow JC: Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-α on eosinophil activation in vitro. Am J Respir Cell Mol Biol 20:474-480.
68. Minty A, Asselin S, Bensussan A, Shire D, Vita N, Vyakarnam A, Wijdenes J, Ferrara P, Caput D: The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur Cytokine Netw 1997, 8:203-213.
69. Gibbs BF, Haas H, Falcone FH, Albrecht C, Vollrath IB, Noll T, Wolff HH, Amon U: Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur J Immunol 1996, 16:2493-2498.
70. Burd PR, Thompson WC, Max EE, Mills FC: Activated mast cells produce interleukin 13. J Exp Med 1995, 181:1373-1380.
71. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G: Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998, 161:5821-5824.
72. de Saint-Vis B, Fugier-Vivier I, Massacriet C, Gaillard C, Vanbervliet B, Ait-Yahia S, Banchereau J, Liu YJ, Lebecque S, Caux C: The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998, 160:1666-1676.
73. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD: Interleukin-13: Central mediator of allergic asthma. Science 1998, 282:2258-2261. Endogenously produced IL-13 is necessary for the mucus and airway hyper- responsiveness, but not eosinophilia or IgE production, in allergen primed mice challenged with inhaled allergen.
74. Bancroft AJ, McKenzie ANJ, Grencis RK: A critical role for IL-13 in resistance to an intestinal nematode infection. J Immunol 1998, 160:453-461. Both IL-4- and IL-13-deficient mice are susceptible to infection with T. muris whereas wild-type littermates are resistant. IL-4-deficient mice make decreased Th2 responses and failed to produce IgG1 antibodies whereas IL-13-deficient mice first make low, then later make normal, Th2 responses but are unable to regulate the magnitude of their antibody isotype response.
75. Morris SC, Madden KB, Adamovicz JJ, Gause WC, Hubbard BR, Gately MK, Finkelman FD: Effects of interleukin-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 1994, 152:1047-1056.
76. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260:547-549.
77. Curiel RE, Lahesmaa R, Subleski J, Cippitelli M, Kirken RA, Young HA, Ghosh P: Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene. Eur J Immunol 1997, 27:1982-1987.
78. Jinquan T, Deleuran B, Gesser H, Maare H, Deleuran M, Larsen CG, Thestrup-Pedersen K: Regulation of human T lymphocyte chemotaxis in vitro by T cell-derived cytokines IL-2, IFN-γ, IL-4, IL-10, and IL-13. J Immunol 1995, 154:3742-3752.
79. McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, Zurwski G, Murray R, Grencis R, McKenzie ANJ: Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998, 9:423-432. Th2 cells generated using T cells from IL-13-deficient mice make less IL-4, IL-5 and IL-10 than wild-type mice whereas mast cells from these mice make similar levels of type 2 cytokines. In vitro type 2 cytokine responses are not rescued by added IL-13 but in vivo addition of IL-13 can increase Th2 responses, as can N. brasiliensis infection. IL-13 deficient mice have lower basal serum IgE levels and biased antigen specific immunoglobulin isotype responses.
80. Emson CL, Bell SE, Jones A, Wisden W, McKenzie ANJ: Interleukin (IL)-4-independent induction of Immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med 1998, 188:399-404. Transgenic overexpression of IL-13 depresses thymocyte development and increases B cell expression of CD23 and serum levels of IgE, even in IL-4-deficient mice.
81. Lai YH, Mosmann TR: Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production. J Immunol 1999, 162:78-87. IL-13 can act directly on mouse B cells to increase their survival.
82. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA: IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999, 162:920-930. In vivo blockade of IL-13 reduces pulmonary granuloma size and total serum IgE levels in mice injected with S. mansoni eggs but did not affect cytokine responses whereas IL-4 deficient mice make lower IL-13 levels than wild-type mice. Granuloma size is also reduced in IL-4 deficient mice and granulomas and pulmonary eosinophilia are nearly absent in IL-13 suppressed, IL-4 deficient mice.
83. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:807-815. Overexpression of IL-13 on a lung-specific promoter induces an eosinophil and mononuclear pulmonary infiltrate, multinucleated pulmonary macrophages, airway epithelial cell hyperplasia, mucus cell metaplasia, increased mucus production, subepithelial airway fibrosis, increased eotaxin production, increased baseline airway resistance and hyper-responsiveness to methacholine.
84. Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB: Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998, 282:2261-2263. Nasal administration of either IL-4 or IL-13 to mice induces an IL-4Rα dependent, asthma like phenotype with airway hyper-responsiveness, eosinophil and neutrophil infiltrates and goblet cell hyperplasia in wild-type mice and mice deficient in B and T cells. Neutralization of endogenously produced IL-13 inhibits airway hyper-responsiveness, pulmonary eosinophilia and goblet cell hyperplasia in allergen primed mice that then inhale the same allergen.
85. Malabarba MG, Rui H, Deutsch H H, Chung J, Kalthoff FS, Farrar WL, Kirken RA: Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-γ and interleukin-4 receptor-α. Biochem J 1996, 319:865-872.